Swedish medtech and pharmaceutical company Sedana Medical AB (Nasdaq First North Growth Market:SEDANA) revealed on Wednesday that it has applied to conduct phase III pivotal clinical trials with its Sedaconda products in the United States.
The company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) and is aiming for a combination registration of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane) for inhaled sedation of mechanically ventilated patients in intensive care.
Subject to approval of the IND, Sedana Medical plans to commence patient recruitment at the turn of Q1/Q2 2022 for two multi-centre, randomised controlled, assessor-blinded clinical trials, with the objective to obtain US approval in 2024.
The primary endpoint in each study will be to show that Sedaconda, administered via Sedaconda ACD, is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care unit. The secondary endpoints relate to opioid requirements, spontaneous breathing, wake-up time and cognitive recovery.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data